The US Food and Drug Administration (FDA) recently cleared the Brainsway Deep Transcranial Magnetic Stimulation (TMS) System to be marketed for treatment of an additional disorder.
The efficacy of escitalopram, compared with duloxetine, for the treatment of acute major depressive disorder varied over multiple measures, but escitalopram showed higher tolerability than duloxetine in a new study.
The Brainsway Deep Transcranial Magnetic Stimulation (TMS) System can be marketed as a treatment for obsessive compulsive disorder (OCD), the US Food and Drug Administration (FDA) announced.
Between 1 and 2 daily milligrams of adjunctive cariprazine eased depression more than placebo in patients with major depressive disorder, according to a newly published study.
Michael Thase, MD, will review data on emerging medications for depression, outline the pathophysiology of depression, and discuss the limitations of available treatments in a session at the upcoming Psych Congress 2018 conference.